Srikanth Nagalla

2.4k total citations
44 papers, 1.5k citations indexed

About

Srikanth Nagalla is a scholar working on Hematology, Genetics and Cancer Research. According to data from OpenAlex, Srikanth Nagalla has authored 44 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 10 papers in Genetics and 10 papers in Cancer Research. Recurrent topics in Srikanth Nagalla's work include Platelet Disorders and Treatments (9 papers), Cancer-related molecular mechanisms research (9 papers) and MicroRNA in disease regulation (8 papers). Srikanth Nagalla is often cited by papers focused on Platelet Disorders and Treatments (9 papers), Cancer-related molecular mechanisms research (9 papers) and MicroRNA in disease regulation (8 papers). Srikanth Nagalla collaborates with scholars based in United States, New Zealand and Malaysia. Srikanth Nagalla's co-authors include Paul F. Bray, Leonard C. Edelstein, Xianguo Kong, Paolo Fortina, Steven E. McKenzie, Chad A. Shaw, Jing-fei Dong, Eric Londin, Adam Ertel and Isidore Rigoutsos and has published in prestigious journals such as JAMA, Circulation and Nature Medicine.

In The Last Decade

Srikanth Nagalla

40 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srikanth Nagalla United States 14 634 472 416 233 184 44 1.5k
Reinhard Depping Germany 28 1.0k 1.6× 531 1.1× 136 0.3× 205 0.9× 47 0.3× 59 1.7k
V. Costantini Italy 18 244 0.4× 248 0.5× 293 0.7× 268 1.2× 91 0.5× 35 1.1k
Xiaolong Fan China 26 979 1.5× 312 0.7× 154 0.4× 451 1.9× 41 0.2× 72 1.8k
Cristina Pontes Vicente Brazil 22 390 0.6× 204 0.4× 272 0.7× 71 0.3× 100 0.5× 48 1.2k
Maria Laura De Marchis Italy 16 987 1.6× 753 1.6× 132 0.3× 132 0.6× 61 0.3× 49 1.6k
Seema S. Dalal United States 11 670 1.1× 457 1.0× 86 0.2× 306 1.3× 172 0.9× 12 1.7k
Yu Hou China 22 586 0.9× 80 0.2× 918 2.2× 195 0.8× 85 0.5× 78 1.8k
Margarethe Geiger Austria 22 339 0.5× 549 1.2× 658 1.6× 96 0.4× 82 0.4× 78 1.4k
Sheng Gao China 22 1.3k 2.0× 306 0.6× 64 0.2× 356 1.5× 63 0.3× 94 2.2k

Countries citing papers authored by Srikanth Nagalla

Since Specialization
Citations

This map shows the geographic impact of Srikanth Nagalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srikanth Nagalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srikanth Nagalla more than expected).

Fields of papers citing papers by Srikanth Nagalla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srikanth Nagalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srikanth Nagalla. The network helps show where Srikanth Nagalla may publish in the future.

Co-authorship network of co-authors of Srikanth Nagalla

This figure shows the co-authorship network connecting the top 25 collaborators of Srikanth Nagalla. A scholar is included among the top collaborators of Srikanth Nagalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srikanth Nagalla. Srikanth Nagalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hofmann, Sandra L., et al.. (2020). Comparison of low fixed dose versus standard-dose rituximab to treat thrombotic thrombocytopenic purpura in the acute phase and preemptively during remission. Transfusion and Apheresis Science. 59(6). 102885–102885. 6 indexed citations
3.
Bergstrom, Colin P., Ayesha Zia, Ravi Sarode, & Srikanth Nagalla. (2020). Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants. Transfusion and Apheresis Science. 59(5). 102815–102815. 4 indexed citations
4.
Brown, Timothy J., Bonnie C Prokesch, Srikanth Nagalla, & Christian Wysocki. (2019). 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis. Open Forum Infectious Diseases. 6(Supplement_2). S175–S176. 1 indexed citations
5.
6.
Nagalla, Srikanth & Ravi Sarode. (2019). Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy. Transfusion Medicine Reviews. 33(2). 92–97. 14 indexed citations
7.
Geethakumari, Praveen Ramakrishnan, Patrick Mille, Rakesh Gulati, & Srikanth Nagalla. (2017). Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfusion and Apheresis Science. 56(3). 400–403. 11 indexed citations
8.
Moore, Joseph A., et al.. (2017). Thyroid storm and warm autoimmune hemolytic anemia. Transfusion and Apheresis Science. 56(4). 606–608. 3 indexed citations
9.
Gupta, Arjun, David H. Johnson, & Srikanth Nagalla. (2017). Antiphospholipid Antibodies. JAMA. 318(10). 959–959. 3 indexed citations
10.
Nagalla, Srikanth & Samir K. Ballas. (2016). Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews. 10. CD003426–CD003426. 18 indexed citations
11.
Geethakumari, Praveen Ramakrishnan, et al.. (2016). “The Immune Conundrum”: Acquired Hemophilia A, Immune Thrombocytopenia, and Neutropenia in a Patient with Pancreatic Cancer. PubMed. 2(1). 14–18. 1 indexed citations
12.
Alistar, Angela, et al.. (2014). Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine. 6(10). 80–80. 1 indexed citations
13.
Alistar, Angela, Jeff W. Chou, Srikanth Nagalla, et al.. (2014). Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine. 6(10). 80–80. 42 indexed citations
14.
Bray, Paul F., Steven E. McKenzie, Leonard C. Edelstein, et al.. (2013). The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 14(1). 1–1. 407 indexed citations
15.
Sasongko, Teguh Haryo, Srikanth Nagalla, & Samir K. Ballas. (2013). Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database of Systematic Reviews. CD009191–CD009191. 8 indexed citations
16.
Edelstein, Leonard C., Lukas M. Simon, Michael Holinstat, et al.. (2013). Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nature Medicine. 19(12). 1609–1616. 161 indexed citations
17.
Nagalla, Srikanth & Samir K. Ballas. (2012). Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews. CD003426–CD003426. 9 indexed citations
18.
Edelstein, Leonard C., Lukas M. Simon, Angela L. Bergeron, et al.. (2012). A Large Cluster of Micrornas At 14q32 Defines an RNA Expression Module That Accounts for Racial Differences in Protease Activated Receptor 4-Mediated Platelet Reactivity. Blood. 120(21). 380–380. 1 indexed citations
19.
Hong, Wei, Altaf A. Kondkar, Srikanth Nagalla, et al.. (2011). Transfection of Human Platelets with Short Interfering RNA. Clinical and Translational Science. 4(3). 180–182. 20 indexed citations
20.
Nagalla, Srikanth, Xianguo Kong, Lin Ma, et al.. (2010). Platelet Microrna-mRNA Co-Expression Profiles Correlate with Platelet Reactivity. Blood. 116(21). 2016–2016. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reinhard Depping Breakdown of academic impact, for papers by V. Costantini Breakdown of academic impact, for papers by Xiaolong Fan Breakdown of academic impact, for papers by Cristina Pontes Vicente Breakdown of academic impact, for papers by Maria Laura De Marchis Breakdown of academic impact, for papers by Seema S. Dalal Breakdown of academic impact, for papers by Yu Hou Breakdown of academic impact, for papers by Margarethe Geiger Breakdown of academic impact, for papers by Sheng Gao
Rankless by CCL
2026